Vertex’s 22% Sales Growth And Pipeline Gives Biotech Something To Smile About

Sickle Cell Therapy Could Be Next Blockbuster

 
• By Andrew McConaghie
  
Vertex HQ, Boston
Vertex's full year results exceeded expectations, and could help revive flagging faith in biotech stocks. • Source: Getty Images
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip